O Shaughnessy Asset Management LLC Sells 1,875 Shares of Stryker Co. (NYSE:SYK)

O Shaughnessy Asset Management LLC reduced its stake in shares of Stryker Co. (NYSE:SYKGet Rating) by 20.4% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 7,334 shares of the medical technology company’s stock after selling 1,875 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Stryker were worth $1,459,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Clearbridge Investments LLC raised its holdings in Stryker by 664.0% during the second quarter. Clearbridge Investments LLC now owns 2,199,253 shares of the medical technology company’s stock valued at $437,497,000 after buying an additional 1,911,376 shares in the last quarter. Perigon Wealth Management LLC raised its holdings in Stryker by 7.2% during the second quarter. Perigon Wealth Management LLC now owns 1,872 shares of the medical technology company’s stock valued at $372,000 after buying an additional 125 shares in the last quarter. FORA Capital LLC bought a new position in Stryker during the second quarter valued at about $2,550,000. Donaldson Capital Management LLC raised its holdings in Stryker by 2.3% during the second quarter. Donaldson Capital Management LLC now owns 2,226 shares of the medical technology company’s stock valued at $443,000 after buying an additional 51 shares in the last quarter. Finally, Watchman Group Inc. raised its holdings in Stryker by 3.0% during the second quarter. Watchman Group Inc. now owns 17,687 shares of the medical technology company’s stock valued at $3,518,000 after buying an additional 510 shares in the last quarter. 76.44% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Stryker

In other Stryker news, Director Srikant M. Datar sold 600 shares of Stryker stock in a transaction that occurred on Wednesday, November 2nd. The stock was sold at an average price of $216.71, for a total transaction of $130,026.00. Following the sale, the director now directly owns 5,161 shares of the company’s stock, valued at $1,118,440.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Srikant M. Datar sold 600 shares of Stryker stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $216.71, for a total value of $130,026.00. Following the completion of the transaction, the director now owns 5,161 shares in the company, valued at $1,118,440.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 340 shares of Stryker stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $219.68, for a total transaction of $74,691.20. Following the completion of the transaction, the vice president now owns 12,774 shares of the company’s stock, valued at approximately $2,806,192.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,240 shares of company stock valued at $268,425. 6.70% of the stock is currently owned by corporate insiders.

Stryker Stock Up 1.7 %

NYSE SYK opened at $230.29 on Thursday. The company has a current ratio of 2.04, a quick ratio of 1.19 and a debt-to-equity ratio of 0.77. The stock’s 50 day moving average is $215.86 and its two-hundred day moving average is $214.51. The company has a market capitalization of $87.15 billion, a price-to-earnings ratio of 35.81, a PEG ratio of 2.80 and a beta of 0.99. Stryker Co. has a 1-year low of $188.84 and a 1-year high of $280.43.

Stryker (NYSE:SYKGet Rating) last released its quarterly earnings data on Monday, October 31st. The medical technology company reported $2.12 earnings per share for the quarter, missing analysts’ consensus estimates of $2.23 by ($0.11). The company had revenue of $4.48 billion for the quarter, compared to analyst estimates of $4.46 billion. Stryker had a net margin of 13.69% and a return on equity of 22.27%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.20 earnings per share. Equities analysts forecast that Stryker Co. will post 9.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Canaccord Genuity Group lowered Stryker from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $225.00 to $220.00 in a research note on Tuesday, November 1st. Jefferies Financial Group assumed coverage on Stryker in a research note on Wednesday, October 12th. They issued a “buy” rating and a $270.00 price objective on the stock. Robert W. Baird dropped their price objective on Stryker from $297.00 to $240.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 27th. Wells Fargo & Company lifted their price objective on Stryker from $237.00 to $248.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 1st. Finally, Citigroup dropped their price objective on Stryker from $255.00 to $246.00 in a research note on Wednesday, October 5th. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $247.74.

About Stryker

(Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Further Reading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKGet Rating).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.